Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Wells Fargo & Co (WFC) Price & Performance

Heron Therapeutics IncTrade
Wells Fargo & CoTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Wells Fargo & Co — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while Wells Fargo & Co trades at $87.5 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 4173.8× Heron Therapeutics Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXWFC
Market Cap
$63.41M$264.66B
Sector
HealthFinancials
52-Week High
$1.49$96.40
52-Week Low
$0.33$73.42
Enterprise Value
$161.31M
Dividend Yield
2.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Wells Fargo & Co

Wells Fargo (WFC) trades at $87.25, down 0.4% today, with a bullish technical outlook from moving averages and a consensus price target of $97.64. The stock shows strong profitability with a net income margin of 25.97% and ROE of 13.13%, supported by steady revenue growth to $83.70 billion in 2025. Recent news highlights the launch of tokenized deposits for corporate clients, reflecting innovation in digital banking services.

The stock presents a value opportunity with a P/E of 12.68, but risks include volatile cash flows and recent earnings misses. Upside is driven by analyst optimism and dividend increases, while headwinds involve economic sensitivity and competitive pressures in banking.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Wells Fargo & Co

Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.

Read more on WFC